Info

10. Ravoet C, Feremans W, Husson B, et al.: Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant 18:943, 1996.

11. Dickinson A, Sviland L, Dunn J, et al.: Demonstration of direct involvement of cytokines in graft-versus-host reaction using an in vitro human skin explant model. Bone Marrow Transplant 7:209, 1991.

12. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992.

13. Carayol G, Bourhis JH, Guillard M, et al.: Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation. Transplantation 63:1307, 1997.

14. Dumler J, Beschorner W, Farmer E, et al.: Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 135:1097, 1989.

tissue-specific homing, in combination with lower toxi-city preparative regimens and selective enrichment or depletion of effector T cells, will yield novel and effective alternatives to minimize the risk of GVHD. These approaches, combined with judicious application(s) of immunopharmacologic agents, may prove sufficient to achieve the full curative promise of allogeneic HSCT.

15. Sackstein R: Lymphocyte migration following bone marrow transplantation. Annal New York Acad Sci 770:177, 1995.

16. Sackstein R, Borenstein M: The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Invest Med 43:68, 1995.

17. Sviland L, Pearson A, Green M, et al.: Prognostic importance of histological and immunopathological assessment of skin and rectal biopsies in patients with GVHD. Bone Marrow Transplant 11:215, 1993.

18. Billingham R: The biology of graft-versus-host reaction. Harvey Lect 62:21, 1966.

19. Fischer A, Beschorner W, Hess A: Syngeneic graft-versus-host disease: failure of autoregulation in self/non-self discrimination. Blood 20:493, 1988.

20. Woodruff J, Hansen J, Good R, et al.: The pathology of the graft-versus-host reaction (GVHR) in adult receiving bone marrow transplants.Transplant Proc 8:675, 1976.

21. Horn T, Bauer D, Vogelsang G, et al.: Reappraisal of his-tological features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model.

J Invest Dermatol 103:206, 1994.

22. Lampert I, Janossy G, Suitters A, et al.: Immunological analysis of the skin in graft-versus-host disease. Clin Exp Immunol 50:123, 1982.

23. Kaye V, Neumann P, Kersey J, et al.: Identity of immune cells in graft-versus-host disease of the skin. Am J Pathol 116:436, 1984.

24. Rhoades J, Cibull M, Thompson J, et al.: Role of natural killer cells in the pathogenesis of human acute graft-versus-host disease. Transplantation 56:113, 1993.

25. Takata M, Imai T, Hirone T: Immunoelectron microscopy of acute graft-versus-host disease of the skin after allogeneic bone marrow transplantation. J Clin Pathol 46:801, 1993.

26. Korngold R, Sprent J: Lethal graft-versus-host disease after bone marrow transplantation across minor histo-compatability barriers in mice. J Exp Med 148:1687, 1978.

27. Thomas J, Wakeling W, Imrie S, et al.: Chimerism in skin of bone marrow transplant recipients. Transplantation 38:475, 1984.

28. Chong AF, Scuderi P, Grimes W, et al.: Tumor targets stimulate IL-2 activated killer cells to produce interferon-y and tumor necrosis factor. J Immunol 142:2133, 1989.

29. Xun C, Brown S, Jennings C, et al.: Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Transplantation 56:409, 1993.

30. Ferrara J, Guillen F, van Dijken P, et al.: Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 47:50, 1989.

31. Storb R, Deeg H, Farewell V, et al.: Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986.

32. Storb R, Deeg HF, Farewell V, et al.: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Eng J Med 314:729, 1986.

33. Beatty PG, Clift FM, Mickelson BB, et al.: Marrow transplantation from related donors other than HLA-identi-cal siblings. N Engl J Med 313:765, 1985.

34. Chan KW, Fryer CJ, Danegri JF, Buskard NA, Phillips GL: Allogeneic bone marrow transplantation using partially-matched related donor. Bone Marrow Transplant 2:27, 1987.

35. Chao N, Schmidt C, Nilan J, et al.: Cyclosporine, methotrexate and prednisone compare with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 329:1225, 1993.

36. Ratanatharathorn V, Nash R, Przepiorka D, et al.: Phase III study comparing methotrexate and tracrolimus (Prograf FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 7:2303, 1998.

37. Nash R, Antin J, Karanes C, et al.: Phase III study comparing tacrolimus (FK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host disease (GVHD) after marrow transplantation from unrelated donors. Blood 96:2062, 2000.

38. Cutler C, Kim HT, Hochberg E, et al.: Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328, 2004.

39. Alyea EP, Neuberg D, Cutler C, et al.: Sirolimus, tacrolimus and low dose methotrexate as graft-versus-host disease prophylaxis after matched related and unrelated nonmyeloablative transplantation is well tolerated and associated with low incidence of acute GVHD. Blood 102:711a, 2003.

40. Storb R, Yu C, Wagner JL, et al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048, 1997.

41. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390, 2001.

42. Nash RA, Johnson L, Parker PM, et al.: A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft-

versus-host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): dose escalation of MMF. Blood 102:240a, 2003.

43. Verdonck L, de Gast G, van Heugten H, Dekker A: A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 75:776, 1990.

44. Verdonck L, Dekker A, de Gast G, et al.: Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 83:3090, 1994.

45. Martin P, Hansen J, Torok-Storb B, et al.: Graft failure in patients receiving T-cell-depleted HLA-identical allogeneic bone marrow transplants. Bone Marrow Transplant 3:445, 1988.

46. Butturini A, Gale R: T-cell depletion in bone marrow transplants for leukemia: current results and future directions. Bone Marrow Transplant 3:185, 1988.

47. Marmont A, Horowitz M, Gale R, et al.: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991.

48. Passweg J, Tiberghien P, Cahn J, et al.: Graft-versus-leukemia effects in T lineage and B lineage acute lym-phoblastic leukemia. Bone Marrow Transplant 21:153, 1998.

49. Champlin R, Ho W, Gajewski J, et al.: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418, 1990.

50. Porter DL, Roth MS, McGarigle C, et al.: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994.

51. Porter DL, Antin JH: The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369, 1999.

52. Collins RH Jr, Shpilberg O, Drobyski WR, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997.

53. Porter DL, Collins RH Jr, Hardy C, et al.: Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95:1214, 2000.

54. Sehn LH, Alyea EP, Weller E, et al.: Comparative outcomes of T-cell-depleted and non-T-cell-depleted allo-geneic bone marrow transplantation for chronic myel-ogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 17:561, 1999.

55. Van Rhee F, Feng L, Cullis J, et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leukocyte infusions before the onset of hematologic relapse. Blood 83:3377, 1994.

56. Barrett A, Mavroudis D, Tisdale J, et al.: T-cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-ver-sus-leukemia effect. Bone Marrow Transplant 21:543, 1998.

57. Petz LD, Yam P, Wallace BR, et al.: Mixed hematopoi-etic chimerism following bone marrow transplantation for hematologic malignancies. Blood 70:133, 1987.

58. Sykes M, Sheard MA, Sachs DH, et al.: Graft-versus-host-related immunosuppression induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 168:2391, 1988.

59. Sykes M, Sharabi Y, Sachs D, et al.: Achieving alloen-graftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 3:379, 1988.

60. Sharabi Y, Abraham VS, Sykes M, et al.: Mixed allo-geneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 9:191, 1992.

61. Huss R, Deeg JH, Gooley T, et al.: Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 18:767, 1996.

62. Suttorp M, Schmitz N, Dreger P, et al.: Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA poly-mophisms. Leukemia 7:679, 1993.

63. Socie G, Lawler M, Gluckman E, et al.: Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era. Leuk Res 19:467, 1995.

64. Hagglund L, Bostom L, Remberger M, et al.: Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 16:747, 1995.

65. Hill RS, Pertersen FB, Storb R, et al.: Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 67:811, 1986.

66. Roy DC, Tantravaho R, Murray C, et al.: Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 75:296,1990.

67. Bertheas MF, Lafage P, Levy M, et al.: Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 78:3103, 1991.

68. Ildstad ST, Wren SM, Bluestone JA, et al.: Effect of selective T-cell depletion of host and/or donor bone marrow lymphopoietic repopulation, tolerance, and graft-ver-sus-host disease in mixed allogeneic chimeras (B10 + B10.D2-B10). J Immunol 136:28,1986.

69. Kawai T, Cosimi AB, Colvin RB, et al.: Mixed allogeneic chimerism and renal allograft tolerance in cynomolo-gous monkeys. Transplantation 59:256,1995.

70. Sykes M, Szot GL, Swenson K, Pearson DA: Induction of high levels of allogeneic hematopoietic reconstitution and donor specific tolerance without myelosup-pressive conditioning. Nature Med 3:783,1997.

71. Pelot MR, Pearson DA, Swenson K, et al.: Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 22:133, 1999.

72. Sykes M, Preffer F, Saidman SL, et al.: Mixed lympho-hematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 353:1755, 1999.

73. Spitzer TR, McAfee S, Sackstein R, et al.: Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6:309, 2000.

74. Spitzer TR, McAfee SL, Dey BR, et al.: Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75:1748, 2003.

75. Sykes M, Harty W, Szot G, Pearson D: Interleukin-2 inhibits graft-versus-host disease promoting activity of CD4+ cells while preserving CD4 and CD8-mediated graft-versus-leukemia effects. Blood 83:2560,1994.

76. Sykes M, Abraham V, Harty W, Pearson D: IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150:197, 1993.

77. Sykes M, Szot GL: Nguyen P, Pearson D, et al.: Interkeukin-12 inhibits murine graft-versus-host disease. Blood 86:2429, 1995.

78. Champlin RE, Passweg JR, Zhang MJ, et al.: Interleukin-2 for prevention of graft-versus-host disease after hap-loidentical marrow transplantation. Transplantation 58:858, 1994.

79. Alyea EP, Canning C, Neuberg D, et al.: CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparti-cles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 34:123, 2004.

80. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S: Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 9:355, 2003.

81. Lowsky R, Jones SD, Mitra S, et al.: Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T-cells and low incidences of acute GVHD and tumor relapse. Blood 102:152a, 2003.

82. Colby C, Sykes M, Sachs DH, et al.: Cellular modulation of acute graft-versus-host disease. Biol Blood Marrow Transplant 3:287, 1997.

83. Mehta JPR, Singhal S, Horton C, Treleaven J: Outcome of autologous rescue after failed engraftment of allo-geneic marrow. Bone Marrow Transplant 17:213, 1996.

84. Deeg H, Henslee-Downey P: Management of acute graft-versus-host disease. Bone Marrow Transplant 6:1,1990.

85. Lazarus H, Vogelsang G, Rowe J, et al.: Prevention and treatment of acute graft-versus-host disease: the old and new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 19:577, 1997.

86. Doney K, Weiden P, Storb R, Thomas E: Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithy-mocyte globulin and corticosteroids. Am J Hematol 11:1, 1981.

87. Kennedy M, Deeg J, Strob R, et al.: Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Am J Med 78:978, 1985.

88. Cragg L, Blazar BR, Defor T, et al.: A randomized trial comparing prednisone with antithymocyte globulin/ prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 6:441, 2000.

89. Lee SJ, Zahrieh D, Agura E, et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-vs.-host disease: results of a randomized trial. Blood 104(5):1559—1564, 2004.

90. Oblon D, Elfenbein G, Goedert M, et al.: Successful therapy of acute graft versus host disease (aGVHD) with high dose methyl-prednisolone (MP). Proc Am Assoc Cancer Res 29:82a, 1988.

91. Khoury H, Kashyap A, Adkins DR, et al.: Treatment of steroid-resistant acute graft-versus-host disease with antithymocyte globulin. Bone Marrow Transplant 27:1059, 2001.

92. Couriel DR, Saliba R, Hicks K, et al.: Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. Blood 104(3):649-654, 2004.

93. Przepiorka D, Kerman NA, Ippoliti C, et al.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody for the treatment of acute graft-versus-host disease. Blood 95:83, 2000.

94. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R: Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30:899, 2002.

95. Ho VT, Zahrieh D, Hochberg E, et al.: Safety and efficacy of denileukin diftitox in patients with steroid refractory graft-versus-host disease (GVHD) after allo-geneic hematopoietic stem cell transplantation (HSCT). Blood 102:242a, 2003.

96. Tiberghien P, Reynolds CW, Keller J, et al.: Ganciclovir treatment of herpes simplex thymidine kinase-trans-duced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333, 1994.

97. Sorror ML, Maris MB, Storer B, et al.: Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloab-lative and myeloablative conditioning: influence of pre-transplant comorbidities. Blood 104(5):1550—1558, 2004.

98. Couriel DR, Saliba RM, Giralt S, et al.: Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10:178, 2004.

99. Epstein JB, Truelove EL: Topical cyclosporine in a bioadhesive for treatment of oral licheniod mucosa; reaction: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82:523, 1996.

100. Kiang E, Tesavibul N, Yee R, Kellaway J, Przepiorka D: The use of topical cyclosporine A in ocular graft-versus-host disease. Bone Marrow Transplant 22:147, 1998.

101. Apisarnthanarax N, Donato M, Korbling M, et al.: Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 31:459, 2003.

102. Sullivan KM, Witherspoon RP, Storb R, et al.: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555, 1988.

103. Sullivan KM, Witherspoon RP, Storb R, et al.: Prednisone and azathioprine compared with pred-nisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged throm-bocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988.

104. Kim JG, Sohn SK, Kim DH, et al.:Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 73:56, 2004.

105. Benito AI, Furlong T, Martin PJ, et al.: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924, 2001.

106. Vogelsang GB, Farmer ER, Hess AD, et al.: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055, 1992.

107. Lee SJ, Wegner SA, McGarigle C, Bierer BE, Antin JH: Treatment of chronic graft-versus-host disease with clo-fazimine. Blood 89:2298, 1997.

108. Chiba T, Yokosuka O, Kanda T, et al.: Hepatic graft-ver-sus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid. Liver 22:514, 2002.

This page intentionally left blank

Chapter 99

0 0

Post a comment